Table 1.
P450a | CYP nameb | Biosynthetic pathway | Function(s) | In vitroc/in vivo/structure | PDB ID(s) | Ref. |
---|---|---|---|---|---|---|
AcmG8 | – | Actinomycin G | Hydroxylation (PCP-tethered)d |
–/Y/– | 172 | |
AknT | – | Aclacinomycin A | Glycosyltransferase (GTase) activator | Y/–/– | 202,203 | |
AmphL | 161A3 | Amphotericin B | Hydroxylation | –/Y/– | 204 | |
AmphN | 105H4 | Amphotericin B | Hydroxylation/oxidation to acid | –/Y/– | 178,179 | |
AryC | – | Arylomycin | Biaryl ring coupling (C–C) | –/Y/– | 205 | |
AurH | 151Ae | Aureothin | Hydroxylation/ether formation | Y/Y/Y | 3P3L, 3P3O, 3P3X, 3P3Z | 115–118 |
AveE | 171A1 | Avermectin | Ether formation | –/Y/– | 119 | |
AziB1 | – | Azinomycin B | Hydroxylation | Y/–/– | 74 | |
BecO | 1045A3 | BE-14106 | Hydroxylation | –/Y/– | 206 | |
BorI | – | Borrelidin | Hydroxylation/oxidation to aldehyde/oxidation to nitrile | Y/Y/– | 90 | |
BoxA | 105Ae | Xenobiotics | Hydroxylation | Y/–/– | 131,207 | |
CanCf | 105H5 | Candicidin | Hydroxylation | –/Y/– | 208–211 | |
ChoP | 105C1 | Unknown | Unknown | Y/–/– | 212 | |
ChryOIII | – | Chrysomycin | Desaturation | –/Y/– | 213 | |
CldC | – | Cyslabdan A | Hydroxylation/epoxidation | –/Y/– | 214 | |
ComI | 165E1 | Complestatin | Biaryl ring coupling (C–C) | –/Y/– | 165 | |
ComJ | 165B5 | Complestatin | Biaryl ring coupling (C–O) | –/Y/– | 165 | |
CotB3 | – | Cyclooctatin | Hydroxylation | –/Y/– | 215 | |
CotB4 | – | Cyclooctatin | Hydroxylation | –/Y/– | 215 | |
CSP4 | 107P3 | Xenobiotics | Dealkylation | Y/–/– | 216 | |
CYP102B1 | 102B1 | Fatty acids | Hydroxylation/epoxidation | Y/Y/– | 31,217 | |
CYP102D1 | 102D1 | Fatty acids | Hydroxylation | Y/–/– | 29 | |
CYP105D4 | 105D4 | Xenobiotics | Hydroxylation | Y/–/– | 131 | |
CYP105D5 | 105D5 | Xenobiotics | Hydroxylation | Y/Y/– | 27,31,32,34,131 | |
CYP105D6 | 105D6 | Filipin | Hydroxylation | Y/–/Y | 3ABB | 218 |
CYP105D7 | 105D7 | Pentalenolactone/xenobiotics | Hydroxylation | Y/Y/Y | 4UBS | 48,219–224 |
CYP105F2 | 105F2 | Oleandomycin | Hydroxylation | Y/–/– | 225 | |
CYP105N1 | 105N1 | Coelibactin | Unknown | Y/–/Y | 3TYW, 4FXB | 31,226,227 |
CYP105P1 | 105P1 | Filipin | Hydroxylation | Y/–/Y | 3ABA, 3E5J, 3E5K, 3E5L | 218,228 |
CYP105P2 | 105P2 | Flavones | Hydroxylation | Y/–/Y | 5IT1 | 40,190,229 |
CYP107AJ1 | 107AJ1 | Xenobiotics | Dealkylation | Y/–/– | 154 | |
CYP107L2 | 107L2 | Fatty acids | Unknown | Y/–/Y | 5CJE, 5CWE | 230 |
CYP107P1 | 107P1 | Unknown | Unknown | Y/–/– | 31 | |
CYP107P2 | 107P2 | Xenobiotics | Hydroxylation | Y/–/– | 171 | |
CYP107T1 | 107T1 | Unknown | Unknown | Y/–/– | 31 | |
CYP107U1 | 107U1 | Xenobiotics | Oxidation to ketone | Y/Y/– | 31,231 | |
CYP107W1 | 107W1 | Oligomycin A | Hydroxylation | Y/–/Y | 4WPZ, 4WQ0 | 232,233 |
CYP107Y1 | 107Y1 | Xenobiotics | Hydroxylation | Y/–/– | 171 | |
CYP107Z13 | 107Z13 | Avermectin | Oxidation to ketone | Y/–/– | 133,234 | |
CYP125A2 | 125A2 | Xenobiotics | Hydroxylation | Y/–/– | 171 | |
CYP147F1 | 147F1 | Fatty acids | Hydroxylation | Y/–/– | 235–237 | |
CYP154A1 | 154A1 | Dipentaenone/xenobiotics | Cycloaddition/dealkylation | Y/Y/Y | 1ODO | 30–32,188,207,238 |
CYP154C1 | 154C1 | Pikromycin/methymycin/neomethymycin | Hydroxylation | Y/–/Y | 1GWI | 31,32,239 |
CYP154C3 | 154C3 | Xenobiotics | Hydroxylation | Y/–/– | 45 | |
CYP155A1 | 155A1 | Unknown | Unknown | Y/–/– | 31 | |
CYP156A1 | 156A1 | Unknown | Unknown | Y/–/– | 31 | |
CYP156B1 | 156B1 | Unknown | Unknown | Y/–/– | 31 | |
CYP157A1 | 157A1 | Unknown | Unknown | Y/–/– | 31 | |
CYP157B1 | 157B1 | Unknown | Unknown | Y/–/– | 31 | |
CYP157C1 | 157C1 | Unknown | Unknown | Y/–/– | 31,151 | |
CYP157C4 | 157C4 | Xenobiotics | Dealkylation | Y/–/– | 240 | |
CYP158A1 | 158A1 | Flaviolin | Biaryl ring coupling (C–C) | Y/–/Y | 2DKK, 2NZ5, 2NZA | 31,32,42 |
CYP158A2 | 158A2 | Flaviolin | Biaryl ring coupling (C–C) | Y/–/Y | 1SE6, 1S1F, 1T93, 2D0E, 2D09, 3TZO, 5DE9 | 31,32,42,102,111,112 |
CYP159A1 | 159A1 | Unknown | Unknown | Y/–/– | 31 | |
CYP170A1f | 170A1 | Albaflavenone | Hydroxylation/oxidation to ketone/diphosphate ionization | Y/Y/Y | 3DBG, 3EL3 | 145–147,241 |
CYP170A2 | 170A2 | Albaflavenone | Hydroxylation/oxidation to ketone | –/Y/– | 242 | |
CYP170B1 | 170B1 | Albaflavenone | Hydroxylation/oxidation to ketone | Y/–/– | 147 | |
CYP450Y110 | – | Xenobiotics | Hydroxylation | Y/–/– | 243 | |
CYP51f | 170A1 | Xenobiotics | Dealkylation | Y/Y/– | 244 | |
CYPSvh01f | 105C1 | Xenobiotics | Hydroxylation | Y/–/– | 245 | |
CYPSvu022 | 154He | Xenobiotics | Hydroxylation | Y/–/– | 245 | |
DesVIII | – | Pikromycin | GTase activator | Y/Y/– | 141–143,246,247 | |
DnrQ | 131A1 | Duanorubicin | GTase activator | –/Y/– | 143,246,248 | |
DoxA27952 | 129A2 | Doxorubicin | Hydroxylation/oxidation to ketone | Y/–/– | 35 | |
DoxA29050 | 129A2 | Doxorubicin | Hydroxylation/oxidation to ketone | Y/Y/– | 86,249,250 | |
DoxAC5 | 129A1 | Doxorubicin | Hydroxylation/oxidation to ketone | Y/–/– | 251,252 | |
Ema1 | 107Z12 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema2f | 107Z10 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema3 | 107Z2v2 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema4f | 107Z5v3 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema5 | 107Z6 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema6 | 107Z5v2 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema7 | 107Z3 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema8 | 107Z2v1 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema9 | 107Z11 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema10f | 107Z5v3 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema11 | 107Z1 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema12 | 107Z9 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema13 | 107Z8 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema14f | 107Z10 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema15 | 107Z5v1 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema16 | 107Z4 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
Ema17 | 107Z7 | Xenobiotics | Hydroxylation/oxidation to ketone | Y/–/– | 132 | |
EncR | 107R1 | Enterocin | Hydroxylation | Y/Y/– | 253,254 | |
FcpCf | 105e | Xenobiotics | Hydroxylation | Y/–/– | 38 | |
FilC | – | Filipin | Hydroxylation | –/Y/– | 255 | |
FilD | – | Filipin | Hydroxylation | –/Y/– | 255 | |
FosK | – | Fostriecin | Hydroxylation | –/Y/– | 256 | |
FscPf | 105H5 | Candicidin | Hydroxylation/oxidation to acid | –/Y/– | 209–211 | |
GalD | – | Galbonolide | Hydroxylation or epoxidation | –/Y/– | 257 | |
GbnD | – | Galbonolide | Hydroxylation or epoxidation | Y/–/– | 258 | |
GdmP | 105U1 | Geldanamycin | Desaturation | –/Y/– | 92–94,259 | |
GerPI | – | Dihydrochalcomycin | Epoxidation | –/Y/– | 260 | |
GerPII | – | Dihydrochalcomycin | Hydroxylation | –/Y/– | 260 | |
GfsF | 105e | FD-891 | Hydroxylation/epoxidation | Y/Y/– | 261,262 | |
GilOIII | – | Gilvocarcin | Desaturation | –/Y/– | 213,263 | |
GrhO3 | 105D9 | Griseorhodin | Epoxidation | –/Y/– | 264 | |
HerG | – | Herboxidiene | Hydroxylation | Y/–/– | 265,266 | |
HerO | – | Heronamide | Hydroxylation | Y/Y/– | 46 | |
HlsH | 107e | Halstoctacoanolide | Hydroxylation/oxidation to ketone | –/Y/– | 164 | |
HlsI | 107e | Halstoctacoanolide | Hydroxylation | –/Y/– | 164 | |
HmtN | – | Himastatin | Hydroxylation | Y/Y/Y | 4E2P | 95,126 |
HmtS | – | Himastatin | Biaryl ring coupling (C–C) | –/Y/– | 95 | |
HmtT | – | Himastatin | C–N bond formation | Y/Y/Y | 4GGV | 95,126 |
JulI | – | Julichrome | Biaryl ring coupling (C–C) | Y/Y/– | 96 | |
LkmF | 107A2 | Lankomycin | Hydroxylation | –/Y/– | 267,268 | |
LkmK | 107AP1 | Lankomycin | Hydroxylation | –/Y/– | 267,268 | |
LnmA | 107AC1 | Leinamycin | Hydroxylation | Y/Y/Y | 4Z5P | 269 |
LnmZ | 107AG1 | Leinamycin | Hydroxylation | Y/Y/Y | 4Z5Q | 269 |
LtmK | – | Lactimidomycin | Desaturation | –/Y/– | 91 | |
MeiE | 171A2 | Meilingmycin | Ether formation | –/Y/– | 173,174 | |
MfnN | – | Marfomycin | Hydroxylation | –/Y/– | 270 | |
MgsK | – | iso-Migrastatin | Hydroxylation | –/Y/– | 271 | |
MonD | 124B1 | Monensin | Hydroxylation (ACP-tethered)d |
–/Y/– | 79 | |
NcsB3 | 154J1 | Neocarzinostatin | Hydroxylation | Y /–/– | 272,273 | |
NikF | 105K1 | Nikkomycin | Hydroxylation | –/Y/– | 167,274 | |
NikQ | 162A1 | Nikkomycin | Hydroxylation (PCP-tethered) |
Y/Y/– | 167,168 | |
NovI | 163A1 | Novobiocin | Hydroxylation (PCP-tethered)d |
Y/–/– | 166 | |
NysL | 161A1 | Nystatin | Hydroxylation | Y/Y/– | 180,181,275 | |
NysN | 105H1 | Nystatin | Hydroxylation/oxidation to acid | –/Y/– | 180,181 | |
NzsA | – | Neocarazostatin | Hydroxylation | Y/Y/– | 276 | |
OleP | 107D1 | Oleandomycin/xenobiotics | Epoxidation/hydroxylation | Y/–/Y | 4XE3 | 72,73,131,277,278 |
OleP1 | 235A1 | Oleandomycin | GTase activator | –/Y/– | 248,279 | |
ORF-A | 107C1 | Carbomycin | Epoxidation | Y/–/– | 280 | |
P450CLA | 105M1 | Clavulanic acid | Unknown | Y/–/– | 281 | |
P450mel | 107F1 | Melanin | Biaryl ring coupling (C–C) | Y/Y/– | 103 | |
P450sca-2 | 105A3 | Xenobiotics | Hydroxylation | Y/–/– | 43,282–285 | |
P450sky | 163B3 | Skyllamycin | Hydroxylation (PCP-tethered)d |
Y/Y/Y | 4L0E, 4L0F, 4PWV, 4PXH | 76–78 |
P450SU-1 | 105A1 | Xenobiotics | Hydroxylation/epoxidation/dealkylation | Y/Y/Y | 2ZBX, 2ZBY, 2ZBZ, 3CV8, 3CV9 | 36,131,134–137,139,286–294 |
P450SU-2 | 105B1 | Xenobiotics | Hydroxylation/dealkylation | Y/Y/– | 36,138,286–289,295 | |
P450terf | 107Le | Xenobiotics | Hydroxylation | Y/Y/– | 296,297 | |
PenM | 161C3 | Pentalenolactone | Oxidative rearrangement | Y/Y/– | 113 | |
PikC | 107L1 | Pikromycin/methymycin/neomethymycin/xenobiotics | Hydroxylation/oxidation to ketone | Y/Y/Y | 2BVJ, 2CA0, 2CD8, 2C6H, 2C7X, 2VZM, 2VZ7, 2WH2, 2WI9, 3ZK5, 3ZPI, 4B7D, 4B7S, 4BF4, 4UMZ | 47,65–69,298–306 |
PimD | 161A2 | Pimaricin | Epoxidation | Y/Y/Y | 2XBK, 2X9P | 50,70,71 |
PlaO2 | – | Phenalinolactone | Nonfunctional | –/Y/– | 83 | |
PlaO3 | – | Phenalinolactone | Hydroxylation | –/Y/– | 82 | |
PlaO4 | – | Phenalinolactone | Hydroxylation | –/Y/– | 83 | |
PlaO5 | – | Phenalinolactone | Hydroxylation | Y/Y/– | 83 | |
PldB | 107e | Pladienolide | Hydroxylation | Y/Y/– | 307 | |
PlmS2 | 107L8 | Phoslactomycin | Hydroxylation | Y/Y/– | 308 | |
PntM | 161C2 | Pentalenolactone | Oxidative rearrangement | Y/Y/Y | 5L1O, 5L1P, 5L1Q, 5L1R, 5L1S, 5L1T, 5L1U, 5L1V, 5L1W | 113,114 |
ProP450 | – | Xenobiotics | Hydroxylation | Y/–/– | 49,309 | |
PsmA | 105e | Pladienolide | Hydroxylation | Y/Y/– | 310,311 | |
PtlI | 183A1 | Pentalenolactone | Hydroxylation/oxidation to aldehyde | Y/–/– | 312 | |
PtmO5 | – | Platensimycin | Ether formation | –/Y/– | 120 | |
Qui15 | – | Echinomycin | Hydroxylation (PCP-tethered)d |
–/Y/– | 170 | |
RapJ | 122A2 | Rapamycin | Hydroxylation | –/Y/– | 313,314 | |
RapN | 107G1 | Rapamycin | Hydroxylation | –/Y/– | 313,314 | |
RavOIII | – | Ravidomycin | Desaturation | –/Y/– | 213 | |
RevI | – | Reveromycin | Hydroxylation | Y/Y/Y | 3WVS | 315 |
RmnC | – | Raimonol | Hydroxylation | –/Y/– | 214 | |
SamR0478 | – | Stambomycin | Hydroxylation | –/Y/– | 316 | |
SamR0479 | – | Stambomycin | Hydroxylation | –/Y/– | 316 | |
SanH | 105K2 | Nikkomycin | Hydroxylation | –/Y/– | 317,318 | |
SanQ | 162A2 | Nikkomycin | Hydroxylation (PCP-tethered) |
–/Y/– | 169 | |
Sclav_p0067 | – | (–)-Drimenol | Unknowng | –/Y/– | 319 | |
ScnD | – | Pimaricin | Epoxidation | Y/Y/– | 182,183 | |
ScnG | – | Pimaricin | Hydroxylation/oxidation acid | –/Y/– | 182,183 | |
SgcD3 | 211A1 | C-1027 | Hydroxylation | –/Y/– | 320 | |
SgvP | 107e | Griseoviridin | C–S bond formation | Y/Y/Y | 4MM0 | 129,130,189 |
SKCTCFkbDf | – | FK506/FK520 | Hydroxylation/oxidation to ketone | Y/Y/– | 321 | |
Sl5NT | – | Unknown | Nitration | Y/–/– | 125 | |
SlgO2 | – | Streptolydigin | Hydroxylation/oxidation to ketone | –/Y/– | 322,323 | |
SlStaN | 244A1 | Staurosporine | C–N bond formation | Y/–/– | 127 | |
SMAFkbD | – | FK506/FK520 | Hydroxylation/oxidation to ketone | –/Y/– | 324 | |
SMg15NT | – | Unknown | Nitration | Y/–/– | 125 | |
SoCYP158A2 | 158A2 | Phenol/indole | Hydroxylation | Y/–/– | 325 | |
SoyC | 105D1 | Xenobiotics | Hydroxylation/epoxidation/dealkylation/desaturation | Y/–/– | 37,326–333 | |
Srm13 | – | Spiramycin | Hydroxylation/oxidation to aldehyde | –/Y/– | 334,335 | |
StaF | 165A4 | A47934 | Biaryl ring coupling (C–O) (PCP-tethered) |
Y/Y/Y | 5EX8, 5EX9 | 99,106,107 |
StaG | 165D1 | A47934 | Biaryl ring coupling (C–O) | –/Y/– | 99 | |
StaH | 165B4 | A47934 | Biaryl ring coupling (C–O) (PCP-tethered) |
Y/Y/Y | 5EX6 | 99,106,107 |
StaJ | 165C5 | A47934 | Biaryl ring coupling (C–C) | –/Y/– | 99 | |
StaP | 245A1 | Staurosporine | Biaryl ring coupling (C–C)/oxidative decarboxylation | Y/–/Y | 2Z3T, 2Z3U, 3A1L | 100,101,108–110,336 |
StFkbDf | – | FK506/FK520 | Hydroxylation/oxidation to ketone | Y/Y/– | 337,338 | |
StStaN | 244A1 | Staurosporine | C–N bond formation | –/Y/– | 100,128 | |
StuD1 | – | Thiolactomycin/thiotetronate | Epoxidation (ACP-tethered)d |
–/Y/– | 80 | |
StuD2 | – | Thiolactomycin/thiotetronate | Hydroxylation/oxidation to acid | –/Y/– | 80 | |
Sv5NT | – | Unknown | Nitration | Y/–/– | 125 | |
TamIf | – | Tirandamycin | Hydroxylation/oxidation to ketone/epoxidation | Y/Y/– | 84,85 | |
TetrKf | – | Tetramycin | Hydroxylation | Y/Y/– | 339 | |
ThnC | – | Thienodolin | C–S bond formation | Y/Y/– | 340 | |
TmcR | – | Tautomycetin | Hydroxylation/oxidation to ketone | –/Y/– | 341,342 | |
TrdIf | – | Tirandamycin | Hydroxylation/oxidation to ketone/epoxidation | –/Y/– | 343 | |
TtmDf | – | Tetramycin | Hydroyxlation | Y/Y/–g | 339,344 | |
TtnI | – | Tautomycetin | Hydroxylation/oxidation to ketone | –/Y/– | 345 | |
TxtC | 246A1 | Thaxtomin | Hydroxylation | Y/Y/– | 346 | |
TxtE | – | Thaxtomin | Nitration | Y/Y/Y | 4L36, 4TPO, 4TPN, 5D3U, 5D40 | 122–125,347 |
TylHI | 105L1 | Tylosin | Hydroxylation | –/Y/– | 348–350 | |
TylMIII | – | Tylosin | GTase activator | –/Y/– | 143,246,351 | |
Unk. P450 | – | Xenobiotics | Dealkylation | –/Y/– | 352 | |
XiaM | – | Xiamycin | Hydroxylation/oxidation to acid | Y/Y/– | 89 |
Commonly used P450 names. Duplicated names are differentiated by adding the first letter of the genus and species, e.g., SlStaN = Streptomyces longisporoflavus StaN.
CYP names identified from reference or the Cytochrome P450 Homepage (drnelson.uthsc.edu).163
In this study, heterologous P450 biotransformations are considered in vitro experiments.
P450 acts on a PCP- or ACP-tethered substrate.
Only CYP family or subfamily was given.
CanC = FscP; CYP170A1 = CYP51; CYPSvh01 = FcpC; Ema2 = Ema14; Ema4 = Ema10; StFkbD = SKCTCFkbD; TamI = TrdI; TetrK = TtmD.
The function of Sclav_p0067 is still unknown, but in vivo results support alteration of FPP cyclization by the sesquiterpene synthase Sclav_p0068.319